Literature DB >> 31576289

Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding.

Antonio Passaro1, Letizia Gianoncelli1, Valeria Stati1, Filippo de Marinis1.   

Abstract

Entities:  

Year:  2019        PMID： 31576289      PMCID： PMC6685842          DOI： 10.21037/atm.2019.04.04

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  17 in total

1.  Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:  Stephanie Heon; Beow Y Yeap; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

Review 2.  Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?

Authors:  Chee-Seng Tan; Byoung Chul Cho; Ross A Soo
Journal:  Lung Cancer       Date:  2017-02-22       Impact factor: 5.705

3.  Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Authors:  Suchit H Patel; Andreas Rimner; Amanda Foster; Zhigang Zhang; Kaitlin M Woo; Helena A Yu; Gregory J Riely; Abraham J Wu
Journal:  Lung Cancer       Date:  2017-03-24       Impact factor: 5.705

Review 4.  The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

Authors:  Solange Peters; Christin Bexelius; Veronica Munk; Natasha Leighl
Journal:  Cancer Treat Rev       Date:  2016-03-15       Impact factor: 12.111

5.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P Brown; Yuri Rukazenkov; Suresh S Ramalingam; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 44.544

6.  EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

Authors:  L E L Hendriks; E F Smit; B A H Vosse; W W Mellema; D A M Heideman; G P Bootsma; M Westenend; C Pitz; G J de Vries; R Houben; K Grünberg; M Bendek; E-J M Speel; A-M C Dingemans
Journal:  Lung Cancer       Date:  2014-01-23       Impact factor: 5.705

7.  Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors.

Authors:  Yoshihiko Taniguchi; Akihiro Tamiya; Kenji Nakahama; Yoko Naoki; Masaki Kanazu; Naoki Omachi; Kyoichi Okishio; Takahiko Kasai; Shinji Atagi
Journal:  Oncol Lett       Date:  2017-10-03       Impact factor: 2.967

Review 8.  Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Authors:  Herbert H Loong; Sui-Chun Sampson Kwan; Tony Shu-Kam Mok; Yat-Ming Lau
Journal:  Curr Treat Options Oncol       Date:  2018-09-29

9.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more
  3 in total

1.  Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.

Authors:  Antonio Passaro; Filippo de Marinis
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.

Authors:  Helena A Yu; Luis G Paz-Ares; James Chih-Hsin Yang; Ki Hyeong Lee; Pilar Garrido; Keunchil Park; Joo-Hang Kim; Dae Ho Lee; Huzhang Mao; Sameera R Wijayawardana; Ling Gao; Rebecca R Hozak; Bo H Chao; David Planchard
Journal:  Clin Cancer Res       Date:  2020-10-12       Impact factor: 12.531

Review 3.  Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations.

Authors:  Antonio Marchetti; Fiamma Buttitta; Emanuela D'Angelo
Journal:  Oncotarget       Date:  2022-03-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.